Opthalmic compositions containing selective m1 muscarinic agonists for treating ocular hypertension
CA 2488845 A1 · Owner: Sagara, Yufu · Inventors: Ogidigben, Miller J.; Yamakawa, Takeru; Sagara, Yufu
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to selective m1 muscarinic agonist their use or a , formulation thereof in the treatment of glaucoma and/or other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species particularly humans. , In addition, the present invention relates to the use of the compounds in the treatment of dementia such as Alzheimer's disease and vascular dementia depression, attention deficit disorder sleep disorder, schizophrenia, pain, ischemia atrophic gastritis, and atony of gastrointestinal tract.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 17, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 17, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 17, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.